Danaher Easily Beats Q2 Street View With Growth From Base Business; FY22 Outlook Unchanged
Danaher Corp (NYSE:DHR) has logged Q2 FY22 adjusted EPS of $2.76, up 12% Y/Y, surpassing the estimate of $2.35. Sales…
Disappointing Data Forces Assembly Bio Stop Combo Trial For HBV Infection
Assembly Biosciences Inc (NASDAQ:ASMB) will stop working on its first-generation core inhibitor, vebicorvir (VBR), as it prioritizes its next-gen core…
Chardan Initiates Coverage On These ‘Intriguing Small-Cap Stories”
Chardan Research initiated coverage on Avidity Biosciences Inc (NASDAQ:RNA) with a Buy rating and a price target of $29 and Dyne Therapeutics Inc (NASDAQ:DYN) with…
Portage Biotech Shares Gain On Buying Outstanding Minority Interest In iNKT Platform
Portage Biotech Inc (NASDAQ:PRTG) acquired the remaining 22% stake in its invariant natural killer T cell (iNKT agonist) platform and now…
Read JMP Securities’ Take On Axogen’s Interim Update
Axogen Inc (NASDAQ:AXGN) reported interim Q2 sales expectations of $34.4 million (+2% y/y; +8% excluding Avive sales in 2Q21) ahead of…
Soligenix Shares Gain On HyBrytes Data From Blood Cancer Study
Soligenix Inc (NASDAQ:SNGX) announced the results of its Phase 3 FLASH study evaluating HyBryte (synthetic hypericin) for cutaneous T-cell lymphoma (CTCL)…
AIM ImmunoTech Posts Additional Patient Data From Pancreatic Cancer Study
AIM ImmunoTech Inc (NYSE:AIM) reported follow-on data from its published single-center named patient program. For the study, patients with locally advanced…
AbbVie, iSTAR Medical Inks Strategic Alliance For Glaucoma Treatment
AbbVie Inc (NYSE:ABBV) announced a strategic transaction to develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS)…
Soleno Shares Surge On Regulatory Update For Its Prader-Willi Syndrome Hopeful
Soleno Therapeutics Inc (NASDAQ:SLNO) provided an update following recent communications with the FDA regarding the development of once-daily DCCR (diazoxide choline)…
Elevance Health Raises Annual Profit Guidance
Elevance Health Inc (NYSE:ELV), previously known as Anthem Inc, has reported Q2 FY22 adjusted EPS of $8.04, up 14.4% Y/Y, beating…